

PROSCA'24Global Forum on
Prostate Cancer**PROGRAMME****Global Forum on Prostate Cancer**

29-30 November 2024

Vienna Marriott Hotel, Austria

proscasymposium.org

Welcome

Dear colleagues, dear friends,

Congratulations, you've made it to Vienna, the destination of your PROSCA journey! Some say the journey is more important than the destination. We say: they are equally important. The journey with the patient case challenges was the ideal warm-up for the real workout: PROSCA 2024.

For 2024, our focus remains on identifying the impact that new data and treatments have on best practice, and how to translate these into your daily clinical practice in order to improve patient management.

To achieve this, we will bring together an international multidisciplinary top faculty to present the data along with a panel of experts who will shape these data into recommendations on the spot, in a new discussion-based format where you will also have a voice!

Yes, in only one day and a half, you will:

- **get a full update on prostate cancer**
- **learn from keynote speakers about the major clinical advances for your practice**
- **get the chance to interact and challenge the expert panel during case discussions**
- **share a coffee and your views with top leaders**

Join the discussions and participate in the lively debates! Ready, set, go!

Welcome to Vienna!

Share your photos
and thoughts on X
@mirrorsmed
#PROSCA24



Global organising committee



V r ne Achard
Radiation Oncology
Fribourg, Switzerland



Ashutosh Tewari
Urology
New York, USA



Amit Bahl
Clinical Oncology
Bristol, UK



Bertrand Tombal
Urology
Brussels, Belgium

Local organising committee



Eva Comp rat
Pathology
Vienna, Austria



Oxana Komina
Radiation Oncology
Vienna, Austria



Gero Kramer
Urology
Vienna, Austria



Ursula Vogl
Medical Oncology
Bellinzona, Switzerland



ORGOVYX
(relugolix) 120 mg tablets

Rapid, sustained, surge free
testosterone suppression

accord

One & Only oral ADT*

Join us to
discover the
latest insights

Introducing ORGOVYX® the One & Only oral ADT
for advanced hormone sensitive prostate cancer.^{1,2}

Achieve rapid, sustained and surge-free
testosterone suppression.³

Promotional symposium Prostate Cancer Playback – Highlights of 2024

When: Thursday 28th November, 18:00–20:00 (CET)

Where: Vienna Marriott Hotel, Vienna, Austria

Adverse events should be reported.

For UK HCPs, reporting forms and information can
be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Accord LTD
on +44 (0) 1271 385 257 or email
medinfo@accord-healthcare.com.

For non-UK/EU HCPs, you can also report side
effects directly via the national reporting system listed
in Appendix V of the EU SPC.

Please scan QR
Code for GB PI for
GB HCPs only.



Please scan QR
code for EU SPC.



This material was created by Accord Healthcare Ltd and is intended for Healthcare Professionals only.

Acronyms: *ADT, Androgen Deprivation Therapy; CET, Central European Time; EU, European Union; GB, Great Britain;
HCP, Healthcare Professional; PI, Prescribing Information; QR, quick-response code; SPC, Summary of Product Characteristics.

References: 1. ORGOVYX® Summary of Product Characteristics. 2. Fragkoulis C, et al. *Arab J Urol*. 2021;19(4):460–463.

3. Shore ND, et al. *N Engl J Med*. 2020;382(4):2187–2196.

EUR-Onc-Org-01475 | October 2024

Faculty

Vérane Achard

Radiation Oncology
Fribourg, Switzerland
[@Achard_Verane](#)

Amit Bahl

Clinical Oncology
Bristol, UK

Dirk Beyersdorff

Radiology
Hamburg, Germany

Erik Briers

Patient Representative
Antwerp, Belgium

Elena Castro

Medical Oncology
Madrid, Spain
[@Ecastrumarcos](#)

Amarnath Challapalli

Clinical Oncology
Bristol, UK

Eva Compérat

Pathology
Vienna, Austria
[@evacomperat](#)

Daan De Maeseneer

Medical Oncology
Bruges & Ghent, Belgium
[@daandm](#)

Silke Gillesen

Medical Oncology
Bellinzona, Switzerland
[@Silke_Gillesen](#)

Karolien Goffin

Nuclear Medicine
Leuven, Belgium
[@karolien_goffin](#)

Petros Grivas

Medical Oncology
Seattle, USA
[@PGrivasMDPhD](#)

Alfred Haidenberger

Radiation Oncology
Salzburg, Austria

Ken Herrmann

Nuclear Medicine
Essen, Germany
[@ProfKHerrmann](#)

Peter Hoskin

Clinical Oncology
Northwood & Manchester &
London, UK

Rob Jones

Medical Oncology
Glasgow, UK

Oxana Komina

Radiation Oncology
Vienna, Austria

Suma Konety

Cardio-oncology
Minneapolis, US

Gero Kramer

Urology
Vienna, Austria

Aurelius Omlin

Medical Oncology
Zürich, Switzerland
[@AOmlin](#)

Athanasios Papatsoris

Urology
Athens, Greece

Daniele Raggi

Medical Oncology
London, UK
[@DanieleRaggi83](#)

Johan Stranne

Urology
Gothenburg, Sweden
[@stranne_johan](#)

Ashutosh Tewari (virtual),

Urology
New York, USA
[@AshTewariMD](#)

Derya Tilki

Urology
Hamburg, Germany
[@Tilki_De](#)

Bertrand Tombal

Oncology
Brussels, Belgium
[@BertrandTOMBAL](#)

Fabio Turco

Medical Oncology
Bellinzona, Switzerland
[@fabioturco92](#)

Roderick van den Bergh

Urology
Rotterdam, the Netherlands
[@roodvdb](#)

Ursula Vogl

Medical Oncology
Bellinzona, Switzerland
[@UrsulaVogl](#)

Thomas Zilli

Radiation Oncology
Bellinzona, Switzerland
[@ZilliThomas](#)

Friday 29 November

09:00	Official opening Oxana Komina, Gero Kramer
09:15	Update lecture: Cardiovascular complications related to hormonal therapy: identification, assessment and management Moderator: Athanasios Papatsoris Presenter: Suma Konety
09:45	Low-risk localised PCa Moderators: Oxana Komina, Bertrand Tombal Should we keep calling ISUP 1 (Gleason 3+3) PCa “cancer”? - Erik Briers, Eva Compérat, Roderick van den Bergh Case presentation Active surveillance for low-risk PCa patients: how should it be done? - Dirk Beyersdorff Discussion and Q&A
11:00	Break
11:30	Case discussion session: High-risk localised/locally advanced PCa Moderators: V��rane Achard, Johan Stranne Panel: V��rane Achard, Amarnath Challapalli, Peter Hoskin, Oxana Komina, Johan Stranne, Derya Tilki, Bertrand Tombal, Roderick van den Bergh, Thomas Zilli Mirrors of Medicine – case-based approach - Bertrand Tombal Case presentation - Daan De Maeseneer Regional lymph node staging by PSMA-PET – how should it be done and interpreted? - Ken Herrmann Is there still a role for lymph node dissection in (very) high-risk patients? - Derya Tilki Combination of radiotherapy and systemic treatment for high-risk patients: not one size fits all - Thomas Zilli Discussion and Q&A
13:00	Lunch

Friday 29 November

14:00	Biochemical recurrence following local therapy Moderators: Julien Van Damme, Roderick van den Bergh PET-PSMA in BCR – what to expect? - Karolien Goffin Second chances: tailoring salvage therapies for BCR post-RP - Peter Hoskin Rising again: salvage strategies for BCR post-RT - Alfred Haidenberger Should we EMBARK or not? - Bertrand Tombal Discussion and Q&A
15:30	Update lecture: RARP: surgical techniques and sexual recovery Moderator: Johan Stranne Presenter: Ashutosh Tewari (virtual)
16:00	Break
16:30	Case discussion session: Metastatic hormone-sensitive prostate cancer (mHSPC) Moderators: Elena Castro, Aurelius Omlin Panel: Amit Bahl, Elena Castro, Amarnath Challapalli, Gero Kramer, Aurelius Omlin, Fabio Turco, Julien Van Damme, Roderick van den Bergh, Ursula Vogl, Thomas Zilli Case presentation - Daan De Maeseneer Managing synchronous mHSPC in a changing treatment environment - Gero Kramer Treatment de-escalation: when and how? - Fabio Turco How does the management change if your patient is older and frail? - Ursula Vogl Panel discussion and Q&A
18:00	End of day 1 & reception



Saturday 30 November

08:55	Opening
09:00	Case discussion session: Management of castration-resistant prostate cancer (CRPC) patients Moderators: Rob Jones, Gero Kramer Panel: Amit Bahl, Elena Castro, Amarnath Challapalli, Silke Gillesen, Rob Jones, Gero Kramer, Aurelius Omlin, Daniele Raggi, Fabio Turco, Ursula Vogl Case presentation - Daan De Maeseneer PARP inhibition in patients with CRPC: for everyone? - Elena Castro Radioligand therapy: which one and when? - Amarnath Challapalli Sequencing of therapies following treatment intensification for mHSPC - Daniele Raggi Panel discussion and Q&A
10:30	Evidence and aspirations in managing M1a disease Moderator: Petros Grivas Next-generation imaging in the metastatic setting - Karolien Goffin Case presentation Panel discussion and Q&A - Amit Bahl, Karolien Goffin, Petros Grivas
11:00	Break
11:30	Looking ahead: PCa management in 2025 Moderator: Amit Bahl View of the surgical oncologist - Johan Stranne View of the radiation oncologist - V�rane Achard View of the medical oncologist - Ursula Vogl View of the nuclear medicine specialist - Karolien Goffin Discussion and Q&A
12:15	APCCC highlights Moderators: Silke Gillesen, Aurelius Omlin Panel: Elena Castro, Bertrand Tombal, Fabio Turco, Thomas Zilli
13:00	End of PROSCA



Every week a new case!


Join 4000 colleagues and see what they would do... and what the experts say!

Stay up-to-date about clinical advances in:

- ✓ Prostate cancer
- ✓ Bladder cancer
- ✓ Renal cell carcinoma
- ✓ Breast cancer

Patient cases right into your mailbox!

- ✓ Weekly case challenges
- ✓ Easy & fast to consume
- ✓ Compare with peers and experts
- ✓ Individual pathways with QuickScan
- ✓ Accredited course per topic



Why not join your colleagues...it's free!

ppcp.mirrorsmed.org



Certificate of attendance

- 1 Go to **<https://library.mirrorsmed.org>** and log in using your personal credentials you received by email.
- 2 Go to the section **"My certificates"** and **download** your certificate of attendance.

Certificate of accreditation

- 1 Go to **<https://library.mirrorsmed.org>** and log in using your personal credentials you received by email.
- 2 Go to the section **"My certificates"** and complete the PROSCA **evaluation form**.
- 3 After completion, you can **download** your certificate of accreditation.
- 4 Deadline to complete the evaluation form and download the certificate of accreditation: **31 May 2025**.



Go to **<https://library.mirrorsmed.org>**

X
Spread
the word
@mirrorsmed
#PROSCA24

Practical information



Onsite contacts

General information	Hanne Kraat	+32 479 10 85 98
Exhibitors & sponsors	Luc Van Ruysevelt	+32 476 25 82 94



Opening hours registration & information desk

Friday 29 November:	08:00 - 18:00
Saturday 30 November:	08:00 - 12:00

Accreditation points



PROSCA 2024 - Global Forum on Prostate Cancer (12th edition), Vienna & hybrid, Austria 29/11/2024-30/11/2024,

has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **10.0** European

CME credits (ECMEC®).

Accreditation Statement: Each medical specialist should claim only those credits that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at <https://edhub.ama-assn.org/pages/applications>. Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

PROSCA thanks its sponsors and partners

Principal sponsor

accord

Gold sponsor



Silver sponsor



Bronze sponsors



Educational sponsors



Johnson & Johnson



Partners



MEETING
DESTINATION
VIENNA

Organised by ISSECAM

Meeting
management by



SATELLITE SYMPOSIUM PROSCA'24



Prostate Cancer Playback Highlights of 2024

Thursday, 28 November 2024
18:00-20:00 hrs, Auditorium

Join interactive
polling and
discussion



Faculty



Cosimo De Nunzio
Rome, Italy



Athanasios Papatsoris
Athens, Greece



Thomas Zilli
Bellinzona, Switzerland



Amit Bahl
Bristol, UK

Agenda

18.00-18.15	Welcome, introductions and objectives	<i>Prof. Cosimo De Nunzio (Italy)</i>
18.15-18.45	2024 Highlights – As a Urologist	<i>Prof. Athanasios Papatsoris (Greece)</i>
18.45-19.15	2024 Highlights – As a Radiation Oncologist	<i>Prof. Thomas Zilli (Switzerland)</i>
19.15-19.45	2024 Highlights – As a Medical Oncologist	<i>Prof. Amit Bahl (UK)</i>
19.45-19.55	2025 Outlook – Panel Discussion	<i>Moderated by Prof. Cosimo De Nunzio (Italy)</i>
19.55-20.00	Concluding remarks	<i>Prof. Cosimo De Nunzio (Italy)</i>

This promotional symposium is
organised and funded by

accord

Video of the in-person
symposium will be available
on-demand afterwards

Full invitation
with speaker
biographies





NUBEQA®
(darolutamide) 300 mg tablets

NUBEQA REDUCES THE RISK OF DEATH BY >30% IN mHSPC AND nmCRPC¹⁻³

EFFICACY THAT DOES NOT COMPROMISE TOLERABILITY¹⁻³

APPROVED IN nmCRPC AND IN mHSPC^{1#}

▼ This medicinal product is subject to a additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See SmPC for how to report adverse reactions. **Qualitative and quantitative composition:** Active substance: Each film-coated tablet contains 300 mg of darolutamide. **Excipient with known effect:** Each film-coated tablet contains 186 mg of lactose monohydrate. **List of excipients:** *Tablet core:* Calcium hydroxide phosphate [E 341], Croscarmellose sodium, Lactose monohydrate, Magnesium stearate [E 470(b)], Povidone [E 1201]. *Film-coating:* Hypromellose, Lactose monohydrate, Macrogol [E 1521], Titanium dioxide [E 171]. **Therapeutic indications:** NUBEQA is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease; metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy. **Pharmacotherapeutic group:** Endocrine therapy, anti-androgens; **ATC code:** L02BB06. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients listed. Women who are or may become pregnant. Further information on warnings and precautions for use, interaction, pregnancy and lactation as well as undesirable effects can be found in the published SmPC. **Marketing authorisation holder:** Bayer AG, 51368 Leverkusen, Germany. **Prescription requirement/pharmacy requirement:** Prescription and pharmacy requirement, repeated dispensing prohibited. **Date of revision of the text:** 05/2024.

References: 1. NUBEQA (darolutamide) [summary of product characteristics]. 51368 Leverkusen, Germany: Bayer AG; 05/2024. 2. Smith MR, Hussain M, Saad F, et al; ARASENS Trial Investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. *N Engl J Med.* 2022; 386(12): 1132–1142. 3. Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. *N Engl J Med.* 2020; 383(11): 1040–1049.

This banner is intended for HCPs only.

PP-NUB-AT-0255-1 09/2024

Notes

Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

PROSCA'24

Global Forum on
Prostate Cancer

ALL SESSIONS ARE INTERACTIVE



**JOIN AT
SLIDO.COM
#PROSCA**

OR SCAN



WE LOOK FORWARD TO HEARING YOUR OPINION!